Ontario Bioscience Innovation Organization Announces LifeSciences BC Members to Present at 2021 OBIO Investment Summit

January 28, 2021 – The Ontario Bioscience Innovation Organization (OBIO) has announced that a number of LifeSciences BC member organizations will be featured as presenters in their 2021 edition of the OBIO Investment Summit. The event will be hosted online, February 9-10.

The LifeSciences BC member companies attending from British Columbia include:

ARC Medical Devices is a clinical stage company developing the only liquid medical device that forms a barrier film to prevent surgical adhesions throughout the entire abdominopelvic cavity. Their nonclinical data shows superior efficacy compared with three of the top marketed products. They are currently completing a volume escalation, safety clinical trial. Proceeds from the Series B financing will be used to start and complete a US Phase 2 efficacy and safety clinical trial in 100 patients undergoing pelvic/gynecological surgery; prosecute and maintain eight new patent families and three previously issued patent families; and to support manufacturing and market access/reimbursement activities. For more information, visit arcmedicaldevices.com

Axolotl Biosciences strives to advance the field of medical science through the use of their novel neurobioink. They are developing innovative products that enable the 3D bioprinting of humanized tissue models to advance the field of tissue engineering and regenerative medicine. Axolotl is opening the door to new areas of research by offering the (once impossible) ability to print stem cells into 3D structures. For more information, visit www.axolotlbiosciences.com


Mesentech makes bi-specific small-molecule therapeutics that are selective for both a tissue target and a molecular target. These chemical conjugates liberate the active pharmaceutical only in the targeted tissue thereby eliminating side effects caused by systemic exposure. Mesentech’s lead program is a bone-targeted anabolic that stimulates bone regeneration. It is indicated for severe pediatric osteoporosis caused by brittle bone disease, Duchenne muscular dystrophy and as a consequence of steroid treatment. For more information, visit mesentech.com

 Zucara Therapeutics Inc. is developing ZT-01, a first-in-class, once-daily therapeutic to prevent insulin-induced hypoglycemia in patients using insulin therapy. ZT-01 is designed to inhibit somatostatin, a pancreatic hormone that impairs the glucagon response to hypoglycemia in people with insulin dependent diabetes. ZT-01 restores glucagon secretion to prevent hypoglycemia, which could dramatically change diabetes disease management and improve both patient health and quality of life. Zucara has recently raised US$21M in a Series A financing that provides capital to conduct Phase 1 and 2 clinical trials. Phase 1 trials are underway with results expected in 2021. For more information, visit www.zucara.ca


Best of luck to all of our member companies!